Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
NCT02449603 on ClinicalTrials.gov · last registry update 2018-11-14
An unusually large phase 4: 150 participants, more than double the 75 typical for the stage. The sponsor logged completion for April 2018. Primary outcome, as filed: Change of mean amplitude of glycemic excursions. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Xijing Hospital
- Sponsor type
- Other
- Enrollment
- 150
- Started
- 2015-11
- Primary completion
- 2018-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change of mean amplitude of glycemic excursions
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.